Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, EpiSciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

FLT3 ligand in acute myeloid leukemia: a simple test with deep implications

Pierre Peterlin 1 Patrice Chevallier 2 Steven Knapper 3 Matthew Collin 4 
1 CRCINA-ÉQUIPE 13 - Nuclear Oncology
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
2 CRCINA-ÉQUIPE 1 - Immunobiology of Human αβ and γδ T Cells and Immunotherapeutic Applications
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Abstract : In contrast to Fms-like tyrosine kinase 3 (FLT3), the influence of FLT3 ligand (FLT3L) on acute myeloid leukemia (AML) biology and disease prognosis has been poorly described. Here we provide an overview of the role played by FLT3L in AML. While being a cytokine implicated in the regulation of hematopoiesis, both in normal situation and after intensive chemotherapy, FLT3L has also a role in enhancing proliferation, inhibiting apoptosis and conferring resistance to FLT3 inhibitors in AML. Moreover, recent independent data show how its measurement may be helpful in the disease management. Indeed, FLT3L could provide a low cost, rapid and noninvasive assessment of chemosensitivity and blast clearance that has robust prognostic significance for patients with AML.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03496910
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, December 20, 2021 - 3:17:33 PM
Last modification on : Wednesday, April 27, 2022 - 4:42:26 AM

Links full text

Identifiers

Collections

Citation

Pierre Peterlin, Patrice Chevallier, Steven Knapper, Matthew Collin. FLT3 ligand in acute myeloid leukemia: a simple test with deep implications. Leukemia & lymphoma, Taylor & Francis, 2021, 62 (2), pp.264-270. ⟨10.1080/10428194.2020.1834091⟩. ⟨inserm-03496910⟩

Share

Metrics

Record views

17